

AssayMax™ Human alpha-Fetoprotein ELISA Kit

Assaypro LLC 3400 Harry S Truman Blvd St. Charles, MO 63301 T (636) 447-9175 F (636) 395-7419 www.assaypro.com

For any questions regarding troubleshooting or performing the assay, please contact our support team at support@assaypro.com.

Thank you for choosing Assaypro.

Assay Summary

Step 1. Add 50 μ l of Standard or Sample per well. Incubate 2 hours.

Step 2. Wash, then add 50 μ l of Biotinylated Antibody per well. Incubate 1 hour.

Step 3. Wash, then add 50 μ l of SP Conjugate per well. Incubate 30 minutes.

Step 4. Wash, then add 50 μ l of Chromogen Substrate per well. Incubate 10 minutes.

Step 5. Add 50 μ l of Stop Solution per well. Read at 450 nm immediately.

Symbol Key



Consult instructions for use.

Assay Template

12								
11								
10								
6								
∞								
7								
9								
.c								
4								
ю								
2								
1								
	Ą	В	3	Q	3	Ŧ	9	I

AssayMax™ Human alpha-Fetoprotein (AFP) ELISA Kit

Catalog No. EF6011-7

Sample insert for reference use only

Positive Control Included

Introduction

Alpha-fetoprotein (AFP, alpha-fetoglobulin) is a fetal-specific glycoprotein with a molecular weight of approximately 70 kDa. It is expressed in the embryonic liver by cells of the vitelline sac and by the fetal intestinal tract in the first trimester of pregnancy (1). After birth, the synthesis of alpha-fetoprotein decreases rapidly. In adults, alpha-fetoprotein level is low but detectable (2). Alpha-fetoprotein has no known function in healthy adults. High levels of alpha-fetoprotein in an adult individual may be associated with a hepatocellular carcinoma (HCC), malignant tumor of the liver (1, 3). Thus, the concentration of alpha-fetoprotein in serum can be measured as a first step in HCC diagnosis (4-5). Moreover the elevated level of alpha-fetoprotein has been observed in lung cancer (6), gastric cancer (7-8), yolk sac tumor, and adenocarcinoma (9).

Principle of the Assay

The AssayMax™ Human alpha-Fetoprotein ELISA (Enzyme-Linked Immunosorbent Assay) Kit is designed for detection of alpha-fetoprotein in human plasma and serum samples. This assay employs a quantitative sandwich enzyme immunoassay technique that measures human alpha-fetoprotein in less than 4 hours. A polyclonal antibody specific for human alpha-fetoprotein has been pre-coated onto a 96-well microplate with removable strips. Alpha-fetoprotein in standards and samples is sandwiched by the immobilized antibody and a biotinylated polyclonal antibody specific for human alpha-fetoprotein, which is recognized by a streptavidin-peroxidase (SP) conjugate. All unbound material is washed away and a peroxidase enzyme substrate is added. The color development is stopped and the intensity of the color is measured.

Caution and Warning

 This product is for Research Use Only and is not intended for use in diagnostic procedures.

- Prepare all reagents (diluent buffer, wash buffer, standard, biotinylated antibody, and SP conjugate), as instructed, prior to running the assay.
- Prepare all samples prior to running the assay. The dilution factors for the samples are suggested in this insert. However, the user should determine the optimal dilution factor.
- Spin down the SP conjugate vial and the biotinylated antibody vial before opening and using contents.
- The Stop Solution is an acidic solution.
- The kit should not be used beyond the expiration date.

Reagents

- Human alpha-Fetoprotein Microplate: A 96-well polystyrene microplate (12 strips of 8 wells) coated with a polyclonal antibody against human alpha-fetoprotein.
- Sealing Tapes: Each kit contains 3 precut, pressure sensitive sealing tapes that can be cut to fit the format of the individual assay.
- Human alpha-Fetoprotein Standard: Human alpha-fetoprotein in a buffered protein base (52 ng, lyophilized).
- Biotinylated Human alpha-Fetoprotein Antibody (50x): A 50-fold concentrated biotinylated polyclonal antibody against human alphafetoprotein (120 µl).
- MIX Diluent Concentrate (10x): A 10-fold concentrated buffered protein base (30 ml).
- Wash Buffer Concentrate (20x): A 20-fold concentrated buffered surfactant (30 ml, 2 bottles).
- SP Conjugate (100x): A 100-fold concentrate (80 μl).
- Chromogen Substrate (1x): A stabilized peroxidase chromogen substrate tetramethylbenzidine (7 ml).
- **Stop Solution (1x):** A 0.5 N hydrochloric acid solution to stop the chromogen substrate reaction (11 ml).
- **Positive Control:** 1 vial, lyophilized. See insert CEF60111.

Storage Condition

- Upon arrival, immediately store components of the kit at recommended temperatures up to the expiration date.
- Store SP Conjugate and Biotinylated Antibody at -20°C.
- Store Microplate, Diluent Concentrate (10x), Wash Buffer, Stop Solution, and Chromogen Substrate at 2-8°C.
- Unused microplate wells may be returned to the foil pouch with the desiccant packs and resealed. May be stored for up to 30 days in a vacuum desiccator.

 Store Standard at 2-8°C before reconstituting with Diluent and at -20°C after reconstituting with Diluent.

Other Supplies Required

- Microplate reader capable of measuring absorbance at 450 nm
- Pipettes (1-20 μl, 20-200 μl, 200-1000 μl, and multiple channel)
- Deionized or distilled reagent grade water

Sample Collection, Preparation, and Storage

- Plasma: Collect plasma using one-tenth volume of 0.1 M sodium citrate as an anticoagulant. Centrifuge samples at 3000 x g for 10 minutes and collect plasma. A 2-fold sample dilution is suggested into MIX Diluent; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles (EDTA or Heparin can also be used as an anticoagulant).
- Serum: Samples should be collected into a serum separator tube. After clot formation, centrifuge samples at 3000 x g for 10 minutes and remove serum. A 2-fold sample dilution is suggested into MIX Diluent; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles.

Applicable samples may also include biofluids, cell culture, and tissue homogenates. If necessary, user should determine optimal dilution factor depending on application needs.

Refer to Dilution Guidelines for further instruction.

	Guidelines for Dilutions of 100-fold or Greater (for reference only; please follow the insert for specific dilution suggested)					
100x		10000x				
A)	4 μl sample : 396 μl buffer (100x) = 100-fold dilution	A) B)	4 μl sample : 396 μl buffer (100x) 4 μl of A : 396 μl buffer (100x)			
	Assuming the needed volume is less than or equal to 400 μl.	5,	= 10000-fold dilution Assuming the needed volume is less than or equal to 400 µl.			
1000x			100000x			
A) B)	4 μl sample : 396 μl buffer (100x) 24 μl of A : 216 μl buffer (10x) = 1000-fold dilution	A) B) C)	4 μl sample : 396 μl buffer (100x) 4 μl of A : 396 μl buffer (100x) 24 μl of B : 216 μl buffer (10x) = 100000-fold dilution			
	Assuming the needed volume is less than or equal to 240 μl.		Assuming the needed volume is less than or equal to 240 μ l.			

Reagent Preparation

- Freshly dilute all reagents and bring all reagents to room temperature before use.
- MIX Diluent Concentrate (10x): Dilute the MIX Diluent Concentrate 10fold with reagent grade water to produce a 1x solution. When diluting
 the concentrate, make sure to rinse the bottle thoroughly to extract any
 precipitates left in the bottle. Mix the 1x solution gently until the crystals
 have completely dissolved. Store for up to 30 days at 2-8°C.
- Human alpha-Fetoprotein Standard: Reconstitute the Human alpha-Fetoprotein Standard (52 ng) with 1.3 ml of MIX Diluent to generate a 40 ng/ml standard stock solution. Allow the vial to sit for 10 minutes with gentle agitation prior to making dilutions. Prepare duplicate or triplicate standard points by serially diluting from the standard stock solution (40 ng/ml) 2-fold with equal volume of MIX Diluent to produce 20, 10, 5, 2.5, 1.25, and 0.625 ng/ml solutions. MIX Diluent serves as the zero standard (0 ng/ml). Any remaining stock solution should be stored at -20°C and used within 30 days. Avoid repeated freeze-thaw cycles.

Standard Point	Dilution	[AFP] (ng/ml)
P1	1 part Standard (40 ng/ml)	40
P2	1 part P1 + 1 part MIX Diluent	20
Р3	1 part P2 + 1 part MIX Diluent	10
P4	1 part P3 + 1 part MIX Diluent	5.0
P5	1 part P4 + 1 part MIX Diluent	2.5
Р6	1 part P5 + 1 part MIX Diluent	1.25
P7	1 part P6 + 1 part MIX Diluent	0.625
P8	MIX Diluent	0.0

- Biotinylated Human alpha-Fetoprotein Antibody (50x): Spin down the antibody briefly and dilute the desired amount of the antibody 50-fold with MIX Diluent to produce a 1x solution. The undiluted antibody should be stored at -20°C.
- Wash Buffer Concentrate (20x): Dilute the Wash Buffer Concentrate 20fold with reagent grade water to produce a 1x solution. When diluting
 the concentrate, make sure to rinse the bottle thoroughly to extract any
 precipitates left in the bottle. Mix the 1x solution gently until the crystals
 have completely dissolved.
- SP Conjugate (100x): Spin down the SP Conjugate briefly and dilute the desired amount of the conjugate 100-fold with MIX Diluent to produce a 1x solution. The undiluted conjugate should be stored at -20°C.

Assay Procedure

- Prepare all reagents, standard solutions, and samples as instructed. Bring all reagents to room temperature before use. The assay is performed at room temperature (20-25°C).
- Remove excess microplate strips from the plate frame and return them immediately to the foil pouch with desiccants inside. Reseal the pouch securely to minimize exposure to water vapor and store in a vacuum desiccator.
- Add 50 µl of Human alpha-Fetoprotein Standard or sample to each well.
 Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 2 hours. Start the timer after the last addition.
- Wash the microplate manually or automatically using a microplate
 washer. Invert the plate and decant the contents; hit 4-5 times on
 absorbent material to completely remove the liquid. If washing
 manually, wash five times with 200 µl of Wash Buffer per well. Invert the
 plate each time and decant the contents; hit 4-5 times on absorbent
 material to completely remove the liquid. If using a microplate washer,

- wash six times with 300 μ l of Wash Buffer per well; invert the plate and hit 4-5 times on absorbent material to completely remove the liquid.
- Add 50 µl of Biotinylated Human alpha-Fetoprotein Antibody to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 1 hour.
- Wash the microplate as described above.
- Add 50 µl of SP Conjugate to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 30 minutes. Turn on the microplate reader and set up the program in advance.
- Wash the microplate as described above.
- Add 50 µl of Chromogen Substrate to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Incubate in ambient light for 10 minutes or until the optimal blue color density develops.
- Add 50 µl of Stop Solution to each well. The color will change from blue to yellow. Gently tap plate to ensure thorough mixing. Break any bubbles that may have formed.
- Read the absorbance on a microplate reader at a wavelength of 450 nm immediately. If wavelength correction is available, subtract readings at 570 nm from those at 450 nm to correct optical imperfections.
 Otherwise, read the plate at 450 nm only. Please note that some unstable black particles may be generated at high concentration points after stopping the reaction for about 10 minutes, which will reduce the readings.

Data Analysis

- Calculate the mean value of the duplicate or triplicate readings for each standard and sample.
- To generate a standard curve, plot the graph using the standard concentrations on the x-axis and the corresponding mean 450 nm absorbance (OD) on the y-axis. The best fit line can be determined by regression analysis using log-log or four-parameter logistic curve fit.
- Determine the unknown sample concentration from the Standard Curve and multiply the value by the dilution factor.

Typical Data


The typical data is provided for reference only. Individual laboratory
means may vary from the values listed. Variations between laboratories
may be caused by technique differences.

Standard Point	ng/ml	OD	Average OD
P1	40	2.396	2.462
		2.528	21.102
P2	20	1.847	1.810
		1.773	2.020
Р3	10	1.125	1.111
13	10	1.097	1.111
P4	5.0	0.675	0.652
F 4	5.0	0.629	0.032
P5	2.5	0.405	0.394
P3	0.383	0.383	0.394
P6	1 25	0.257	0.263
PO	P6 1.25 0.269	0.269	0.203
P7	0.625	0.183	0.179
Ρ/	0.025	0.175	0.179
P8	0.0	0.114	0.117
РО	0.0	0.120	0.117
Sample: Pooled Normal		0.291	0.204
Sodium Citrat	e Plasma (2x)	0.311	0.301
Sample: Poo	oled Normal	0.419	0.400
Serun	n (2x)	0.385	0.402

Standard Curve

• The curve is provided for illustration only. A standard curve should be generated each time the assay is performed.

Human alpha-Fetoprotein Standard Curve



Reference Values

- Normal human alpha-fetoprotein plasma and serum levels range from 1 – 8 ng/ml.
- Plasma and serum samples from healthy adults were tested (n=40). On average, human alpha-fetoprotein level was 4.4 ng/ml.

Sample	n	Average Value (ng/ml)
Pooled Normal Plasma	10	3.6
Normal Plasma	20	4.2
Pooled Normal Serum	10	5.4

 This cell line was tested in house (n=10). The cell line average is provided for reference only.

Cell Lysate	Dilution Factor	Average Value (ng/mg cell lysate)
HepG2 (human hepatocellular carcinoma)	2x	3.854

Performance Characteristics

- The minimum detectable dose of human alpha-fetoprotein as calculated by 2SD from the mean of a zero standard was established to be 0.41 ng/ml.
- Intra-assay precision was determined by testing three plasma samples twenty times in one assay.
- Inter-assay precision was determined by testing three plasma samples in twenty assays.

	Intra-Assay Precision			Inter	-Assay Pred	ision
Sample	1	2	3	1	2	3
n	20	20	20	20	20	20
CV (%)	5.2%	6.3%	5.6%	9.5%	11.2%	10.7%
Average CV (%)		5.7%			10.5%	

Recovery

Standard Added Value	1.25 – 10 ng/ml	
Recovery %	90 – 111%	
Average Recovery %	98%	

Linearity

• Plasma and serum samples were serially diluted to test for linearity.

Average Percentage of Expected Value (%)			
Sample Dilution	Plasma	Serum	
1x	96%	95%	
2x	101%	98%	
4x	105%	104%	

• Cell lysate samples were serially diluted to test for linearity.

Average Percentage of Expected Value (%)			
Sample Dilution	HepG2 (human hepatocellular carcinoma)		
	Cell Lysate		
1x	95%		
2x	102%		
4x	104%		

Cross-Reactivity

Species	Cross-Reactivity (%)
Canine	<30%
Bovine	<30%
Equine	None
Monkey	<40%
Mouse	None
Rat	None
Swine	None
Rabbit	None

Troubleshooting

Issue	Causes	Course of Action
Low Precision	Use of improper	Check the expiration date listed before use.
	components	 Do not interchange components from different lots.
		Check that the correct wash buffer is being used.
	Improper wash step	 Check that all wells are empty after aspiration.
		 Check that the microplate washer is dispensing properly.
		 If washing by pipette, check for proper pipetting
		technique.
	Splashing of reagents while loading wells	Pipette properly in a controlled and careful manner.
	Inconsistent volumes	 Pipette properly in a controlled and careful manner.
	loaded into wells	 Check pipette calibration.
	loaded lifto wells	Check pipette for proper performance.
	Insufficient mixing of reagent dilutions	 Thoroughly agitate the lyophilized components after
		reconstitution.
	0	Thoroughly mix dilutions.
	Improperly sealed	 Check the microplate pouch for proper sealing.
		Check that the microplate pouch has no punctures.
	microplate	Check that three desiccants are inside the microplate
		pouch prior to sealing.
Unexpectedly Low or High Signal Intensity	Microplate was left unattended between	Each step of the procedure should be performed
	steps	uninterrupted.
	Omission of step	• Consult the provided precedure for complete list of stone
	Steps performed in	 Consult the provided procedure for complete list of steps. Consult the provided procedure for the correct order.
	incorrect order	• consult the provided procedure for the correct order.
	Insufficient amount of	Check pipette calibration.
	reagents added to	Check pipette for proper performance.
	wells	
<u>≥</u> ⊆	Wash step was skipped	 Consult the provided procedure for all wash steps.
ected	Improper wash buffer	 Check that the correct wash buffer is being used.
	Improper reagent	 Consult reagent preparation section for the correct
х	preparation	dilutions of all reagents.
Une	Insufficient or	 Consult the provided procedure for correct incubation
	prolonged incubation	time.
	periods	
Curve Fit		Sandwich ELISA: If samples generate OD values higher the state and and a size (P1) dilute as a sample.
		than the highest standard point (P1), dilute samples further and repeat the assay.
	Non-optimal sample	Competitive ELISA: If samples generate OD values lower
	dilution	than the highest standard point (P1), dilute samples
	G.130011	further and repeat the assay.
2		User should determine the optimal dilution factor for
ıdε		samples.
Deficient Standard Curve Fit	Contamination of	A new tip must be used for each addition of different
	reagents	samples or reagents during the assay procedure.
	Contents of wells	Verify that the sealing film is firmly in place before placing
	evaporate	the assay in the incubator or at room temperature.
)ef		 Pipette properly in a controlled and careful manner.
	Improper pipetting	 Check pipette calibration.
		 Check pipette for proper performance.

Insufficient mixing of reagent dilutions	Thoroughly agitate the lyophilized components after reconstitution. Thoroughly mix dilutions.
--	---

References

- (1) Gomaa AI et al. (2009) World J Gastroenterol. 15(11):1301-1314.
- (2) Blohm ME et al. (1998) Pediatr Hematol Oncol. 15(2):135-142.
- (3) Sell S. (2008) Tumour Biol. 29(3):161-180.
- (4) Maringhini A et al. (1988) Digestive Diseases and Sciences. 33(1):47-51.
- (5) Chen L et al. (2010) Ann Surg Oncol. 17(9):2518-2525.
- (6) Hiroshima K et al. (2002) Pathol Int. 52:46-53.
- (7) Chen J et al. (2003) Dig Dis. 21:357-362.
- (8) Kelleher J et al. (1974) Gut. 15:401-403.
- (9) Pauniaho SL et al. (2010) Tumour Biol. 31(4):261-265.

Version 2.7R-7